WO2007030375A3 - Lysosomal acid lipase therapy for nafld and related diseases - Google Patents

Lysosomal acid lipase therapy for nafld and related diseases Download PDF

Info

Publication number
WO2007030375A3
WO2007030375A3 PCT/US2006/034044 US2006034044W WO2007030375A3 WO 2007030375 A3 WO2007030375 A3 WO 2007030375A3 US 2006034044 W US2006034044 W US 2006034044W WO 2007030375 A3 WO2007030375 A3 WO 2007030375A3
Authority
WO
WIPO (PCT)
Prior art keywords
nafld
acid lipase
lysosomal acid
therapy
combination therapy
Prior art date
Application number
PCT/US2006/034044
Other languages
French (fr)
Other versions
WO2007030375A2 (en
Inventor
Gregory A Grabowski
Original Assignee
Childrens Hosp Medical Center
Gregory A Grabowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center, Gregory A Grabowski filed Critical Childrens Hosp Medical Center
Priority to US12/065,975 priority Critical patent/US20090297496A1/en
Publication of WO2007030375A2 publication Critical patent/WO2007030375A2/en
Publication of WO2007030375A3 publication Critical patent/WO2007030375A3/en
Priority to US14/245,042 priority patent/US20140234288A1/en
Priority to US15/236,609 priority patent/US20160367645A1/en
Priority to US16/142,136 priority patent/US20190125842A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,
PCT/US2006/034044 2005-09-08 2006-08-31 Lysosomal acid lipase therapy for nafld and related diseases WO2007030375A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/065,975 US20090297496A1 (en) 2005-09-08 2006-08-31 Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US14/245,042 US20140234288A1 (en) 2005-09-08 2014-04-04 Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US15/236,609 US20160367645A1 (en) 2005-09-08 2016-08-15 Lysosomal acid lipase therapy for nafld and related diseases
US16/142,136 US20190125842A1 (en) 2005-09-08 2018-09-26 Lysosomal acid lipase therapy for nafld and related diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71503605P 2005-09-08 2005-09-08
US60/715,036 2005-09-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/065,975 A-371-Of-International US20090297496A1 (en) 2005-09-08 2006-08-31 Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US14/245,042 Continuation US20140234288A1 (en) 2005-09-08 2014-04-04 Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases

Publications (2)

Publication Number Publication Date
WO2007030375A2 WO2007030375A2 (en) 2007-03-15
WO2007030375A3 true WO2007030375A3 (en) 2008-01-24

Family

ID=37836350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034044 WO2007030375A2 (en) 2005-09-08 2006-08-31 Lysosomal acid lipase therapy for nafld and related diseases

Country Status (2)

Country Link
US (4) US20090297496A1 (en)
WO (1) WO2007030375A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328446T5 (en) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Use of lysosomal acid lipase to treat atherosclerosis and associated diseases
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8455432B2 (en) 2007-01-25 2013-06-04 Verva Pharmaceuticals Ltd. Insulin sensitisers and methods of treatment
AU2015249135A1 (en) * 2010-04-23 2015-11-19 Synageva Biopharma Corp. Lysosomal storage disease enzyme
CA2995446C (en) * 2010-04-23 2020-05-12 Synageva Biopharma Corp Lysosomal storage disease enzyme
CA2808039A1 (en) * 2010-08-12 2012-02-16 Kyorin Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for non-alcoholic steatohepatitis
CA3209456A1 (en) 2010-09-09 2012-04-19 Alexion Pharmaceuticals, Inc. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
KR20140006037A (en) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 Methods for treating lysosomal acid lipase deficiency
WO2012112677A2 (en) * 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
RU2733544C2 (en) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Conjugate containing oxintomodulin and immunoglobulin fragment, and its application
ES2748158T3 (en) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising oxyntomodulin and an immunoglobulin fragment
EP3182979B1 (en) 2014-08-20 2023-12-06 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
TWI802396B (en) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
WO2017049161A1 (en) * 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
WO2017079748A1 (en) * 2015-11-06 2017-05-11 Gemphire Therapeutics, Inc. Treatment of mixed dyslipidemia
CA3009630C (en) 2015-12-16 2023-08-01 Amastan Technologies Llc Spheroidal dehydrogenated metals and metal alloy particles
AU2020264446A1 (en) 2019-04-30 2021-11-18 6K Inc. Mechanically alloyed powder feedstock
WO2021118762A1 (en) 2019-11-18 2021-06-17 6K Inc. Unique feedstocks for spherical powders and methods of manufacturing
US11590568B2 (en) 2019-12-19 2023-02-28 6K Inc. Process for producing spheroidized powder from feedstock materials
EP4173060A1 (en) 2020-06-25 2023-05-03 6K Inc. Microcomposite alloy structure
AU2021349358A1 (en) 2020-09-24 2023-02-09 6K Inc. Systems, devices, and methods for starting plasma
AU2021371051A1 (en) 2020-10-30 2023-03-30 6K Inc. Systems and methods for synthesis of spheroidized metal powders
CN114470000A (en) * 2020-11-11 2022-05-13 上海萨美细胞技术有限公司 Application of cell-free fat extract in treating nonalcoholic steatohepatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036754A2 (en) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US6849257B2 (en) * 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
WO2005123117A1 (en) * 2004-06-21 2005-12-29 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of non alcoholic steatotic hepatitis (nash)

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (en) * 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
JPS6038490A (en) * 1983-08-11 1985-02-28 Toshiba Corp White light-emitting phosphor mixture and cathode-ray tube using the same
US5387413A (en) * 1985-06-14 1995-02-07 The Research Foundation Of State University Of New York Method of inhibiting thrombus formation by the 7E3 monoclonal antibody
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4772684A (en) * 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5017716A (en) * 1987-05-22 1991-05-21 E.R. Squibb & Sons, Inc. Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method
US4997837A (en) * 1987-09-08 1991-03-05 Warner-Lambert Company 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4994494A (en) * 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US5081127A (en) * 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US4946864A (en) * 1988-02-01 1990-08-07 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5021453A (en) * 1988-03-02 1991-06-04 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US4920109A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Antifungal compositions and method of controlling mycotic infections
US4897402A (en) * 1988-06-29 1990-01-30 Merck & Co., Inc. 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors
IT1226726B (en) * 1988-07-29 1991-02-05 Zambon Spa ACTIVE COMPOUNDS AS CHOLESTEROL BIOSYNTHESIS INHIBITORS.
US5196440A (en) * 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
DE3832570A1 (en) * 1988-09-24 1990-03-29 Hoechst Ag 7-SUBSTITUTED DERIVATIVES OF 3,5-DIHYDROXYHEPT-6-ACID, METHODS FOR THE PRODUCTION THEREOF, THEIR USE AS MEDICINAL PRODUCTS AND INTERMEDIATE PRODUCTS
US4906657A (en) * 1988-12-21 1990-03-06 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4957940A (en) * 1988-12-21 1990-09-18 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4950675A (en) * 1988-12-21 1990-08-21 Warner-Lambert Company Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis
US4923861A (en) * 1989-02-07 1990-05-08 Warner-Lambert Company 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5130306A (en) * 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) * 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5102911A (en) * 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4992429A (en) * 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
US5098931A (en) * 1989-08-31 1992-03-24 Merck & Co., Inc. 7-substituted HMG-CoA reductase inhibitors
IT1237793B (en) * 1989-12-21 1993-06-17 Zambon Spa ACTIVE COMPOUNDS AS INHIBITORS OF THE HMG-COA REDUCTASE ENZYME
US5025000A (en) * 1990-03-02 1991-06-18 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitor compounds
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5085992A (en) * 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5182298A (en) * 1991-03-18 1993-01-26 Merck & Co., Inc. Cholesterol lowering agents
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
US5286895A (en) * 1992-02-19 1994-02-15 Merck & Co., Inc. Cholesterol lowering compounds
US5302604A (en) * 1992-03-09 1994-04-12 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
US5283256A (en) * 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
US5279940A (en) * 1992-08-03 1994-01-18 Eastman Kodak Company Chemiluminescent composition containing cationic surfactants or polymers and 4'-hydroxyacetanilide, test kits and their use in analytical methods
US5317031A (en) * 1992-10-19 1994-05-31 Merck & Co., Inc. Cholesterol lowering compounds
GB9225098D0 (en) * 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6105571A (en) * 1992-12-22 2000-08-22 Electrosols, Ltd. Dispensing device
GB9410658D0 (en) * 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
US6103271A (en) * 1994-12-02 2000-08-15 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulation and electrostatic processing method
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
DE69637875D1 (en) * 1995-09-14 2009-04-30 Virginia Tech Intell Prop Production of lysosomal enzymes in plant expression systems
US5873523A (en) * 1996-02-29 1999-02-23 Yale University Electrospray employing corona-assisted cone-jet mode
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5900360A (en) * 1996-04-10 1999-05-04 Welch; William J. Correction of genetic defects using chemical chaperones
BR9810372A (en) * 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Nucleic acid transfer process into cells of multicellular eukaryotic organisms in vivo, composition, nucleic acid and electric field, and, combination product
US5904646A (en) * 1997-09-08 1999-05-18 Jarvik; Robert Infection resistant power cable system for medically implanted electric motors
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2389627T3 (en) * 1998-07-20 2012-10-29 Virbac (Australia) Pty Ltd Formulation for bioimplants
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000034451A1 (en) * 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
AU4979700A (en) * 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US7927587B2 (en) * 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP2002090878A (en) * 2000-09-20 2002-03-27 Seiko Epson Corp Projector
WO2003002153A1 (en) * 2001-06-28 2003-01-09 Wyeth Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
AU2003207744A1 (en) * 2002-01-30 2003-09-02 Yale University Transport peptides and uses therefor
WO2003087833A2 (en) * 2002-04-16 2003-10-23 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A marker for measuring liver cirrhosis
CA2499188A1 (en) * 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (en) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Application of isoflavones and their derivatives in Mucopolysacharidose treatment
US8143265B2 (en) * 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
US8466118B2 (en) * 2007-04-23 2013-06-18 Saint Louis University Modulation of blood brain barrier protein expression
CN101686996B (en) * 2007-05-31 2012-12-05 格莱肯生物科学公司 New application of sulphated xylans for treatment or prophylaxis of respiratory diseases
EP2167135A2 (en) * 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
US8183003B2 (en) * 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) * 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
CN102647905B (en) * 2009-10-19 2015-09-09 阿米库斯治疗学公司 For preventing and/or treating the novel composition of Lysosomal storage disorder
CA2995446C (en) * 2010-04-23 2020-05-12 Synageva Biopharma Corp Lysosomal storage disease enzyme
CA3209456A1 (en) * 2010-09-09 2012-04-19 Alexion Pharmaceuticals, Inc. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849257B2 (en) * 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
WO2002036754A2 (en) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
WO2005123117A1 (en) * 2004-06-21 2005-12-29 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of non alcoholic steatotic hepatitis (nash)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREA A, MOSQUERA D, MARTIN E, ARIZTI A, CORDERO J L, ROS E: "Nonalcoholic fatty liver disease is associated with carotid atherosclerosis - A case-control study", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 25, no. 5, May 2005 (2005-05-01), pages 1045 - 1050, XP002440703, ISSN: 1079-5642 *
COLLANTES R, ONG J P; YOUNOSSI Z M: "Nonalcoholic fatty liver disease and the epidemic of obesity", CLEVELAND CLINIC JOURNAL OF MEDICINE, vol. 71, no. 8, August 2004 (2004-08-01), pages 657 - 664, XP002440701, ISSN: 0891-1150 *
DU H ET AL: "ENZYME THERAPY FOR LYSOSOMAL ACID LIPASE DEFICIENCY IN THE MOUSE", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 16, 1 August 2001 (2001-08-01), pages 1639 - 1648, XP001118104, ISSN: 0964-6906 *
MARCHESINI G, BRIZI M, BIANCHI G, TOMASSETTI S, BUGIANESI E.: "Nonalcoholic fatty liver disease: A feature of the metabolic syndrome", DIABETES, vol. 50, no. 8, August 2001 (2001-08-01), pages 1844 - 1850, XP002440702, ISSN: 0012-1797 *

Also Published As

Publication number Publication date
US20160367645A1 (en) 2016-12-22
US20190125842A1 (en) 2019-05-02
US20140234288A1 (en) 2014-08-21
WO2007030375A2 (en) 2007-03-15
US20090297496A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
EP2636404A3 (en) Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
EP3241558A3 (en) Highly soluble leptins
WO2009028457A1 (en) Therapeutic agent for nonalcoholic steatohepatitis
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2013009539A8 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2007092772A3 (en) Protein formulations
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2007054279A8 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
TW200630327A (en) Substituted phenylalkanoic acids
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
EA200701519A1 (en) LIVE ATTENUATED ROTAVIRAL VACCINE FOR ORAL ADMINISTRATION
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2006055725A3 (en) Substituted amino acids as protein tyrosine phosphatase inhibitors
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004099168A3 (en) Substituted carboxylic acids
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12065975

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06802718

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06802718

Country of ref document: EP

Kind code of ref document: A2